Search our Database of Scientific Publications and Authors

I’m looking for a

    3734 results match your criteria Plaque Psoriasis

    1 OF 75

    Density of mast cells and intensity of pruritus in psoriasis vulgaris: a cross sectional study.
    An Bras Dermatol 2018 Jun;93(3):368-372
    Service of Dermatology, Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil.
    Background: Psoriasis is a chronic and prevalent disease, and the associated pruritus is a common, difficult-to-control symptom. The mediators involved in psoriatic pruritus have not been fully established.

    Objective: To evaluate associations between the number of mast cells in psoriatic lesions and the intensity of pruritus. Read More

    Tazarotene gel with narrow-band UVB phototherapy: a synergistic combination in psoriasis.
    An Bras Dermatol 2018 Jun;93(3):385-390
    Department of Dermatology, Venereology and Leprology, Pandit B.D. Sharma Post Graduate Institute of Medical Sciences, Rohtak, Haryana, India.
    Background: Narrow-band UVB (NB-UVB) has been shown to be one of the most effective treatment modalities for psoriasis. Tazarotene, a known effective anti-psoriatic modality, when combined with NB-UVB may enhance the therapeutic success.

    Objective: To study clinical efficacy and safety of combination of NB-UVB with topical tazarotene 0. Read More

    Keratinocytes derived from late-onset psoriasis skin do not impair Langerhans cell migration.
    Br J Dermatol 2018 Jun 19. Epub 2018 Jun 19.
    The University of Manchester, Manchester Academic Health Science Centre, Salford Royal NHS Foundation Trust, Manchester, M6 8HD.
    Chronic plaque psoriasis (CPP) is associated with over-expression of interleukin (IL)-17 and systemic antibody therapies targeting this cytokine are highly efficacious . Psoriasis presents as either early- or late-onset disease (before or after 40 years of age, respectively). Langerhans cells (LC) are the dendritic cells of the epidermis that regulate cutaneous immune responses . Read More

    Phase 3 randomised study of the proposed biosimilar adalimumab GP2017 in psoriasis - impact of multiple switches.
    Br J Dermatol 2018 Jun 19. Epub 2018 Jun 19.
    Central Dermatology, St Louis, MO, U.S.A.
    Background: The impact of multiple switches between GP2017 and reference adalimumab (ref-ADMB) was assessed following the demonstration of equivalent efficacy and similar safety and immunogenicity, in adult patients with active, clinically stable, moderate-to-severe plaque psoriasis.

    Methods: This 51-week double-blinded, phase 3 study randomly assigned patients to GP2017 (N=231) or ref-ADMB (N=234) 80 mg subcutaneously at Week 0, then 40 mg biweekly from Week 1. At Week 17, patients were re-randomised to switch (n=126) or continue (n=253) treatment. Read More

    Guselkumab, an anti-interleukin-23 monoclonal antibody, for the treatment of moderate to severe plaque-type psoriasis in Japanese patients: Efficacy and safety results from a phase 3, randomized, double-blind, placebo-controlled study.
    J Dermatol 2018 Jun 15. Epub 2018 Jun 15.
    The Jikei University School of Medicine, Tokyo, Japan.
    Previous global studies of guselkumab have demonstrated clinical benefits in patients with psoriasis. The aim of this 52-week, phase 3 study was to evaluate efficacy and safety of guselkumab in Japanese patients with moderate to severe plaque-type psoriasis. Patients randomly received guselkumab 50 mg or 100 mg at weeks 0, 4 and every 8 weeks, or placebo with cross-over to guselkumab 50 mg or 100 mg at week 16. Read More

    A safety evaluation of Guselkumab for the treatment of psoriasis.
    Expert Opin Drug Saf 2018 Jun 13. Epub 2018 Jun 13.
    a Dermatology, Department of "Medicina dei Sistemi" , University of Rome Tor Vergata , Rome.
    Introduction: Guselkumab is a fully human monoclonal IgG1λ antibody for the treatment of plaque psoriasis that inhibits interleukin (IL)-23p19 subunit, reducing the proliferation of type 17 helper T (Th-17) cells and thus production of Th-17-derived pro-inflammatory cytokines, especially IL-17 and IL-22. Areas covered: In the following article, the mechanism of action and mainly the efficacy and safety profile of guselkumab available from results of trials will be discussed. We summarized these data after a literature review including PubMed search, relating proceedings and abstracts from relevant international conferences, assessment reports from European and United States regulatory agencies and treatment guidelines up to April 2018. Read More

    Functional role of human interleukin-32 and nuclear transcription factor-kB in patients with psoriasis and psoriatic arthritis.
    Int J Health Sci (Qassim) 2018 May-Jun;12(3):29-34
    Department of Medical Biochemistry, College of Medicine, Qassim University, Buraidah, KSA.
    Objective: Inflammation and its associated cell signaling events have been well documented in psoriasis and psoriatic arthritis. However, the potential for interleukin (IL)-32 and its associated signaling to provoke an inflammatory response or to contribute in the pathogenesis of psoriasis or psoriatic arthritis are still in early phase. This study determined the role of IL-32 and nuclear transcription factor (NF)-κB in patients with plaque psoriasis and psoriatic arthritis. Read More

    Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study.
    Lancet 2018 Jun 1;391(10136):2213-2224. Epub 2018 Jun 1.
    Immunology, Janssen Research & Development, Spring House, PA, USA.
    Background: Guselkumab, a human monoclonal antibody that binds to the p19 subunit of interleukin 23, has been approved for the treatment of moderate-to-severe psoriasis. Psoriatic arthritis is a common comorbidity of psoriasis with an umet need for novel treatments. We assessed the efficacy and safety of guselkumab in patients with active psoriatic arthritis. Read More

    Economic burden, work and school productivity in individuals with tuberous sclerosis and their families.
    J Med Econ 2018 Jun 11:1-17. Epub 2018 Jun 11.
    f Riley Hospital for Children , 705 Riley Hospital Dr. #4300 , Indianapolis IN 46202 , USA.
    Aims: Tuberous sclerosis complex (TSC) is a multi-organ autosomal-dominant, genetic disorder with incomplete penetrance. The multiple manifestations of TSC and impacts to numerous organ systems represent significant disease, health care and treatment burden. The economic and employment burden of the disease on individuals and their families is poorly understood. Read More

    Exposure-Response Modeling to Characterize the Relationship Between Ixekizumab Serum Drug Concentrations and Efficacy Responses at Week 12 in Patients With Moderate to Severe Plaque Psoriasis.
    J Clin Pharmacol 2018 Jun 7. Epub 2018 Jun 7.
    Dermatologikum Berlin and SCIderm Research Institute, Hamburg, Germany.
    Ixekizumab, a high-affinity monoclonal antibody, selectively targets interleukin-17A and has been shown to be efficacious in the treatment of moderate to severe psoriasis. The objective was to describe the relationship between ixekizumab concentrations and efficacy response (static Physician Global Assessment [sPGA] and the Psoriasis Activity and Severity Index [PASI) scores] after 12 weeks of ixekizumab treatment in psoriasis patients from 3 phase 3 studies. Data from 2888 psoriasis patients randomized to receive placebo or 80 mg ixekizumab every 2 weeks or every 4 weeks were analyzed. Read More

    Dermoscopic patterns of early-stage mycosis fungoides in a Chinese population.
    Clin Exp Dermatol 2018 Jun 6. Epub 2018 Jun 6.
    Department of Dermatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
    Background: Early-stage mycosis fungoides (eMF) is a clinical diagnostic challenge because it can mimic inflammatory diseases. Dermoscopy has been reported to be useful in evaluation of eMF in Caucasian patients; however, dermoscopic features of eMF in the Chinese population are lacking.

    Aim: To determine the validity of dermoscopy in the diagnosis and differential diagnosis of eMF in a Chinese population. Read More

    Cost-effectiveness analysis of sequential biologic therapy with ixekizumab versus secukinumab as first-line treatment of moderate-to-severe psoriasis in the UK.
    J Med Econ 2018 Jun 6:1-11. Epub 2018 Jun 6.
    a Mapi Group , Stockholm , Sweden.
    Aims: Patients with psoriasis often undergo treatment with a sequence of biologic agents because of poor/loss of response to initial therapy. With the availability of newer agents like ixekizumab and secukinumab, there is a need for cost-effectiveness analyses to better reflect current clinical practice. This study aimed to assess the cost-effectiveness of a sequence of biologic therapies containing first-line ixekizumab vs first-line secukinumab in patients with moderate-to-severe plaque psoriasis in the UK. Read More

    Psoriasis and Psoriatic Spectrum Disease: A Primer for the Primary Care Physician.
    Am J Med 2018 Jun 1. Epub 2018 Jun 1.
    Complex Medical Dermatology Clinic, St. Elizabeth Physicians, Florence, KY.
    Psoriasis is a chronic, immune-mediated disorder that affects approximately 7.5 million people in the United States. Individuals with psoriasis may develop cutaneous, articular, and systemic manifestations, which are a source of significant morbidity, heighted risk of mortality. Read More

    Pharmacokinetic Characteristics of Tofacitinib in Adult Patients With Moderate to Severe Chronic Plaque Psoriasis.
    Clin Pharmacol Drug Dev 2018 Jun 1. Epub 2018 Jun 1.
    Pfizer Inc, Groton, CT, USA.
    Tofacitinib is an oral Janus kinase (JAK) inhibitor. This study characterized the pharmacokinetics of tofacitinib in patients with psoriasis and evaluated the impact of patient factors on disposition. Pooled phase 2/3 data (2981 patients: 9735 concentrations, dose range: 2-15 mg twice daily) up to 56 weeks were used for modeling. Read More

    Generalized pustular psoriasis - A model disease for specific targeted immunotherapy, systematic review.
    Exp Dermatol 2018 May 31. Epub 2018 May 31.
    Department of Dermatology and Allergy Biederstein, Technical University of Munich, Germany.
    Generalized pustular psoriasis (GPP) psoriasis is a rare, multisystemic skin disease characterized by recurrent episodes of pustulation. GPP can be life-threatening and is often difficult to treat. In the era of precision medicine in dermatology, GPP stands exemplary for both challenges and chances - while new treatments offer great hope, there is urgent need for better definition and stratification of this severe and heterogeneous disease. Read More

    Efficacy and Safety of Tripterygium Wilfordii Hook F on Psoriasis Vulgaris: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Evid Based Complement Alternat Med 2018 22;2018:2623085. Epub 2018 Apr 22.
    Department of Dermatology, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou 510120, China.
    Background: Psoriasis is a chronic autoimmune-mediated skin disease that is characterized by persistent localized erythematous scaly plaque. Tripterygium wilfordii Hook F (TwHF), a well-known Chinese medicine that has been used for centuries in China to treat immune diseases, inflammation, and tumor, is accompanied by a degree of toxic effects. Its clinical efficacy and safety on psoriasis are incompletely understood. Read More

    Epidemiology and Clinical Features of Adult Patients with Psoriasis in Malaysia: 10-Year Review from the Malaysian Psoriasis Registry (2007-2016).
    Dermatol Res Pract 2018 23;2018:4371471. Epub 2018 Apr 23.
    Department of Dermatology, Hospital Kuala Lumpur, Kuala Lumpur, Malaysia.
    Background: Psoriasis is a chronic inflammatory skin disease affecting 2-3% of the general population.

    Aim: To evaluate the epidemiology and clinical characteristics of patients with psoriasis who seek treatment in outpatient dermatology clinics throughout hospitals in Malaysia.

    Materials And Methods: Data were obtained from the Malaysian Psoriasis Registry (MPR). Read More

    Determining the Value of Two Biologic Drugs for Chronic Inflammatory Skin Diseases: Results of a Multi-Criteria Decision Analysis.
    BioDrugs 2018 Jun;32(3):281-291
    Fundación Weber, Majadahonda, Madrid, Spain.
    Background And Objective: Multi-criteria decision analysis (MCDA) is a tool that systematically considers multiple factors relevant to health decision-making. The aim of this study was to use an MCDA to assess the value of dupilumab for severe atopic dermatitis compared with secukinumab for moderate to severe plaque psoriasis in Spain.

    Method: Following the EVIDEM (Evidence and Value: Impact on DEcision Making) methodology, the estimated value of both interventions was obtained by means of an additive linear model that combined the individual weighting (between 1 and 5) of each criterion with the individual scoring of each intervention in each criterion. Read More

    Maintenance of Skin Clearance With Ixekizumab Treatment of Psoriasis: Three-Year Results From the UNCOVER-3 Study.
    J Am Acad Dermatol 2018 May 24. Epub 2018 May 24.
    Dermatology Service, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
    Background: Psoriasis, a chronic disease, may require long-term treatment. Ixekizumab, a high-affinity monoclonal antibody that selectively targets interleukin-17A, is an approved therapy for patients with moderate-to-severe plaque psoriasis.

    Objective: To evaluate efficacy and safety of ixekizumab through 156 weeks from the UNCOVER-3 study in patients who received the recommended dose regimen [160 mg at Week 0, 80 mg every 2 weeks (IXE Q2W) to Week 12, and 80 mg every 4 weeks (IXE Q4W) thereafter. Read More

    Efficacy of Guselkumab Compared With Adalimumab and Placebo for Psoriasis in Specific Body Regions: A Secondary Analysis of 2 Randomized Clinical Trials.
    JAMA Dermatol 2018 Jun;154(6):676-683
    Oregon Medical Research Center, Portland.
    Importance: Psoriasis of the scalp, palms and/or soles, and nails is challenging to treat.

    Objective: To evaluate the effect of guselkumab on psoriasis in specific body regions.

    Design, Setting, And Participants: VOYAGE 1 and VOYAGE 2 were, double-blind, placebo- and adalimumab-controlled studies of guselkumab conducted at 101 and 115 global sites, respectively, from November 3, 2014, to May 19, 2016. Read More

    Secukinumab in moderate-to-severe plaque psoriasis: a multi-center, retrospective, real-life study up to 52 weeks observation.
    Expert Opin Biol Ther 2018 Jun 6:1-9. Epub 2018 Jun 6.
    a Dermatology, Department of "Medicina dei Sistemi" , University of Rome Tor Vergata , Rome , Italy.
    Objectives: To evaluate efficacy and safety of the anti-IL-17 drug secukinumab in a real-life large cohort of patients with moderate-to-severe plaque psoriasis in Central Italy.

    Methods: Multicenter, retrospective study with an observation period of up to 52 weeks. Efficacy was assessed by Psoriasis Area and Severity Index (PASI) score; clinical and laboratory examinations were performed at baseline and at weeks 4, 12, 24, 36, and 52. Read More

    Interleukin 23 in the skin: role in psoriasis pathogenesis and selective interleukin 23 blockade as treatment.
    Ther Adv Chronic Dis 2018 May 19;9(5):111-119. Epub 2018 Mar 19.
    The Milstein Research Program, Laboratory Head, Investigative Dermatology, The Rockefeller University, 1230 York Avenue, Box 178, New York, NY 10065, USA.
    Plaque psoriasis is one of the most common autoimmune skin diseases and is characterized by erythematous, scaly plaques. Many highly effective, targeted therapies have been developed as a result of an improved understanding of the pathogenesis of psoriasis. Using agents that target the central interleukin (IL)-23/IL-17 immune axis, this once difficult-to-treat disease is now among the most effectively treated autoimmune diseases with major clinical improvements possible in around 90% of patients. Read More

    A traditional Chinese remedy points to a natural skin habitat: Indirubin (indigo naturalis) for psoriasis and the Malassezia metabolome.
    Br J Dermatol 2018 May 23. Epub 2018 May 23.
    Department of Dermatology Faculty of Medicine, School of Health Sciences, University, Ioannina, Ioannina, 45100, Greece.
    We read with extreme interest the evidence for an impressively high, comparable to current systemic therapies, dose related efficacy of indirubin in plaque psoriasis. Lin and co-authors appropriately discuss their results, yet we would like to draw attention to a noteworthy aspect of the proposed therapeutic modality: The effectiveness of indirubin highlights the significance of the Malassezia metabolome in psoriasis, a long-term disputed issue. This article is protected by copyright. Read More

    Efficacy and Safety Outcomes for Originator TNF Inhibitors and Biosimilars in Rheumatoid Arthritis and Psoriasis Trials: A Systematic Literature Review.
    BioDrugs 2018 Jun;32(3):193-199
    Organización Médica de Investigación, Buenos Aires, Argentina.
    Objective: Regulatory approval of biosimilar versions of originator biotherapeutics requires that new biological products be highly similar to originator products, with no clinically meaningful differences in safety, purity, and potency. In some trials of biosimilars of tumor necrosis factor inhibitors for the treatment of rheumatoid arthritis (RA) and plaque psoriasis (PsO), pre-specified margins for efficacy and safety have been met, but differences in treatment responses between pivotal originator trials and biosimilar trials have been noted. The objective of this systematic review was to examine these differences. Read More

    Early Onset of Clinical Improvement with Ixekizumab in a Randomized, Open-label Study of Patients with Moderate-to-severe Plaque Psoriasis.
    J Clin Aesthet Dermatol 2018 May 1;11(5):33-37. Epub 2018 May 1.
    Dr. Khattri, Dr. Amir, Dr. Min, and Dr. Lebwohl are with the Department of Dermatology at the Icahn School of Medicine at Mount Sinai in New York, New York.
    The purpose of this study was to evaluate the speed of onset of clinical response to ixekizumab (IXE) and assess the progression of visible improvement in patients with moderate-to-severe plaque psoriasis. This was an interventional, randomized, open-label, Phase IIIb clinical trial. This was a single center study at the Mount Sinai School of Medicine. Read More

    Tofacitinib in patients with moderate to severe chronic plaque psoriasis: long-term safety and efficacy in an open-label extension study.
    Br J Dermatol 2018 May 21. Epub 2018 May 21.
    Pfizer Inc, Cambridge, MA, USA.
    Background: Tofacitinib is an oral Janus kinase inhibitor. Final safety and efficacy data from an open-label extension study of tofacitinib in psoriasis are reported.

    Objective: To evaluate the long-term safety and durability of efficacy of tofacitinib in adults with moderate to severe chronic plaque psoriasis. Read More

    Clindamycin-induced Maculopapular Exanthema with Preferential Involvement of Striae Distensae: A Koebner phenomenon?
    Acta Dermatovenerol Croat 2018 Apr;26(1):61-63
    Benigno Monteagudo-Sánchez, MD, Hospital Arquitecto Marcide, Avenida Residencia SN , 15405 Ferrol (A Coruńa), A Coruńa, Spain;
    Clindamycin is a lincomycin-derived antibiotic useful for the treatment of anaerobic and Gram-positive aerobic bacterial infections. Cutaneous adverse reactions are usually maculopapular exanthemas, although hypersensitivity syndrome, acute generalized exanthematous pustulosis, and Stevens-Johnson syndrome have also been reported (1). We report the case of a patient with a maculopapular rash triggered by clindamycin who developed cutaneous lesions on striae distensae (SD). Read More

    Psoriasis Area and Severity Index response in moderate-severe psoriatic patients switched to adalimumab: results from the OPPSA study.
    J Eur Acad Dermatol Venereol 2018 May 18. Epub 2018 May 18.
    Department of Dermatology, University of Rome 'Tor Vergata', Rome, Italy.
    Background: Few studies have compared the efficacy of switching to adalimumab in the real-life setting in plaque psoriasis patients.

    Objective: To evaluate the effect of adalimumab in psoriasis patients previously treated with other biologics.

    Methods: In this multicentre study, psoriasis patients (N = 262) treated with an anti-TNF-alpha agent, ustekinumab or naïve to biologics then switched to adalimumab were included. Read More

    Automated, computer-guided PASI measurements by digital image analysis versus conventional physicians' PASI calculations: study protocol for a comparative, single-centre, observational study.
    BMJ Open 2018 May 17;8(5):e018461. Epub 2018 May 17.
    Department of Dermatology, University Hospital Heidelberg, Heidelberg, Germany.
    Introduction: Reliable and accurate assessment of severity in psoriasis is very important in order to meet indication criteria for initiation of systemic treatment or to evaluate treatment efficacy. The most acknowledged tool for measuring the extent of psoriatic skin changes is the Psoriasis Area and Severity Index (PASI). However, the calculation of PASI can be tedious and subjective and high intraobserver and interobserver variability is an important concern. Read More

    Immunohistochemical expression HIF1α in chronic plaque psoriasis, an association with angiogenesis and proliferation.
    J Immunoassay Immunochem 2018 May 17:1-14. Epub 2018 May 17.
    b Dermatology Departments, Faculty of Medicine , Menoufia University , Shebein Elkom , Egypt.
    Psoriasis is characterized by excessive cell proliferation, angiogenesis, and regions of hypoxia. Hypoxia stimulates production of hypoxia inducible factors (HIFs) such as HIF1α. The aim of the present study is to investigate the possible role of HIF1α in pathogenesis of psoriasis and to correlate its expression with angiogenesis and proliferation in involved and uninvolved skin in patients with plaque psoriasis using CD34 and Ki-67. Read More

    ROC analysis of selected matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) in psoriatic patients.
    Postepy Dermatol Alergol 2018 Apr 24;35(2):167-173. Epub 2018 Apr 24.
    Department of Esthetic Medicine, Medical University of Bialystok, Bialystok, Poland.
    Introduction: Psoriasis is a common, chronic inflammatory disease characterised by typical scaly skin lesions. The role of matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) in the pathogenesis and development of this condition have been repeatedly emphasised in available literature.

    Aim: ROC analysis of selected MMPs (MMP-2, MMP-3, MMP-9, MMP-12, TIMP-2) and TIMPs (TIMP-2, TIMP-3) in psoriasis patients. Read More

    Comparison of NAPSI and N-NAIL for evaluation of fingernail psoriasis in patients with moderate-to-severe plaque psoriasis treated using ustekinumab.
    J Dermatolog Treat 2018 May 25:1-6. Epub 2018 May 25.
    a Department of Dermatology , Seoul National University Bundang Hospital, Seoul National University College of Medicine , Seongnam , Korea.
    Objective: We sought to determine the psoriatic nail feature which responds to ustekinumab treatment more effectively, and evaluate which between the Nail Psoriasis Severity Index (NAPSI) and the Nijmegen-Nail psoriasis Activity Index tooL (N-NAIL) better reflects the clinical improvement of nail psoriasis.

    Methods: Thirty patients with moderate-to-severe plaque psoriasis were prospectively enrolled and treated with ustekinumab for 52 weeks. A single investigator evaluated the condition using the NAPSI and the N-NAIL with serial fingernail photographs. Read More

    Tildrakizumab: First Global Approval.
    Drugs 2018 May 11. Epub 2018 May 11.
    Springer, Private Bag 65901, Mairangi Bay, 0754, Auckland, New Zealand.
    Merck & Company Inc. have developed tildrakizumab (tildrakizumab-asmn; Ilumya™), a high-affinity, humanised IgG1 κ monoclonal antibody that specifically targets interleukin-23 p19, as a treatment for chronic plaque psoriasis. The drug was recently approved for marketing by the US FDA based on positive results from the phase III reSURFACE clinical trial programme in patients with chronic plaque psoriasis. Read More

    Ixekizumab Pharmacokinetics, Anti-Drug Antibodies, and Efficacy through 60 Weeks of Treatment of Moderate-to-Severe Plaque Psoriasis.
    J Invest Dermatol 2018 May 8. Epub 2018 May 8.
    Oregon Medical Research Center, Portland, OR, USA.
    Ixekizumab, a high-affinity monoclonal antibody that selectively targets interleukin-17A, is efficacious for moderate-to-severe plaque psoriasis. We examined relationships between serum ixekizumab concentrations, treatment-emergent anti-drug antibodies (TE-ADA), and efficacy during 60 weeks of treatment in a randomized, controlled, phase 3 study. Steady-state ixekizumab serum trough concentrations were rapidly achieved and associated with high clinical responses at week 12 with a starting dose of 160 mg followed by 80 mg every 2 weeks. Read More

    A non-inferiority randomized controlled clinical trial comparing Unani formulation & psoralen plus ultraviolet A sol in chronic plaque psoriasis.
    Indian J Med Res 2018 Jan;147(1):66-72
    Central Council for Research in Unani Medicine, AYUSH, New Delhi, India.
    Background & Objectives: Though Unani medications have been used for centuries to treat psoriasis, there is paucity of published studies which have systematically evaluated their efficacy and safety. This study was conducted to establish non-inferiority of Unani medications (oral UNIM-401 and topical UNIM-403) vs psoralen plus ultraviolet A (PUVA) sol in treatment of moderate-severe chronic plaque psoriasis (CPP) in achieving psoriasis area severity index (PASI) 75 at 12 wk and to estimate proportion of patients who relapsed in follow up period of 12 weeks, after having achieved PASI 50.

    Methods: In this randomized, controlled trial patients with CPP were block randomized to receive either Unani treatment (147 patients) or PUVA sol (140 patients) for 12 weeks. Read More

    Efficacy and Safety of Ixekizumab in a Randomized, Double-Blinded, Placebo-Controlled Phase 3b Study of Patients with Moderate-to-Severe Genital Psoriasis.
    Br J Dermatol 2018 May 10. Epub 2018 May 10.
    Eli Lilly and Company, Indianapolis, IN, USA.
    Background: Genital psoriasis (GenPs) is a common, debilitating, and difficult to treat manifestation of plaque psoriasis. However, few controlled, interventional studies of GenPs exist.

    Objective: To determine the efficacy of ixekizumab versus placebo in patients with moderate-to-severe GenPs with BSA≥1%. Read More

    Emergence of Inflammatory Bowel Disease During Treatment with Secukinumab.
    J Crohns Colitis 2018 May 9. Epub 2018 May 9.
    UGC Enfermedades Digestivas. Hospital Universitario de Valme. Sevilla, España.
    Secukinumab is an anti-IL 17A monoclonal antibody currently licensed for the treatment of plaque psoriasis, psoriatic arthritis and ankylosing spondylitis. However, although inflammatory bowel disease is a disorder with related immune characteristics, secukinumab has not proved to be effective in these diseases. In fact, negative results in a clinical trial designed to assess its efficacy in patients with Crohn disease have been published. Read More

    Safety of Tildrakizumab for Moderate-to-Severe Plaque Psoriasis: Pooled Analysis of Three Randomised Controlled Trials.
    Br J Dermatol 2018 May 9. Epub 2018 May 9.
    Merck& Co., Inc., Kenilworth, NJ, USA.
    Background: Short-term IL-23p19 inhibition by tildrakizumab improves plaque psoriasis and appears well-tolerated.

    Objectives: Safety/tolerability were assessed for up to 64 weeks of tildrakizumab therapy using pooled data from 3 randomised controlled trials for moderate-to-severe psoriasis.

    Methods: Data pools for the placebo-controlled (up to 16 weeks) and full-trial periods (up to 64 weeks) were analysed (N=2081). Read More

    Asian consensus on assessment and management of mild to moderate plaque psoriasis with topical therapy.
    J Dermatol 2018 May 9. Epub 2018 May 9.
    Department of Dermatology, Guro Hospital, College of Medicine, Korea University, Seoul, Korea.
    A working group of dermatologists in Asian countries assessed the current status of psoriatic management in the region to prepare a consensus report on topical treatment in mild to moderate plaque psoriasis. Even though the association of psoriasis with systemic comorbidities is increasingly acknowledged, psoriasis is still lower in health-care priority lists in the region. The psychosocial impact of psoriasis may be greater in Asian countries due to cultural norms and social discrimination. Read More

    Systematic review of anti-drug antibodies of IL-17 inhibitors for psoriasis.
    J Dermatolog Treat 2018 May 18:1-7. Epub 2018 May 18.
    c Department of Dermatology , Kaiser Permanente Los Angeles Medical Center , Los Angeles , CA , USA.
    Three main biologics target the IL-17 pathway; these include secukinumab, ixekizumab, brodalumab, all of which are approved for treatment of moderate-to-severe plaque psoriasis. We performed a systematic review of the literature to determine if IL-17 inhibitors are prone to develop anti-drug antibodies (ADA) and how efficacy of treatment is influenced. A total of 14 papers were reviewed. Read More

    Stricturing and Fistulizing Crohn's Disease Is Associated with Anti-tumor Necrosis Factor-Induced Psoriasis in Patients with Inflammatory Bowel Disease.
    Dig Dis Sci 2018 May 8. Epub 2018 May 8.
    Division of Gastroenterology, Department of Medicine, Mount Sinai Hospital IBD Centre, University of Toronto, 441-600 University Avenue, Toronto, ON, M5G 1X5, Canada.
    Background: Paradoxical development of psoriasis in patients on anti-TNF agents has been increasingly reported.

    Aim: The aim was to characterize the prevalence and clinical characteristics of anti-TNF-associated psoriasis in a large cohort of inflammatory bowel disease patients.

    Methods: Medical records of patients with Crohn's disease or ulcerative colitis treated with anti-TNF therapy at a single, tertiary IBD center were identified between 2004 and 2016. Read More

    Patient Perceptions of Clear/Almost Clear Skin in Moderate-to-Severe Plaque Psoriasis: Results of the Clear About Psoriasis Worldwide Survey.
    J Eur Acad Dermatol Venereol 2018 May 6. Epub 2018 May 6.
    The Dermatology Centre, Salford Royal NHS Foundation Trust, NIHR Manchester Biomedical Research Centre, The University of Manchester, Manchester Academic Health Science Centre, Manchester, UK.
    Background: Therapeutic advances have made the achievement of clear/almost clear skin possible for many patients with moderate-to-severe plaque psoriasis.

    Objective: To determine patient perceptions of the impact of psoriasis and of attaining clear/almost clear skin.

    Methods: Global survey of patients with moderate-to-severe psoriasis. Read More

    Maintenance of therapeutic response over one year using apremilast combination therapy compared to monotherapy for the treatment of plaque psoriasis: a multicenter, retrospective study.
    J Am Acad Dermatol 2018 May 3. Epub 2018 May 3.
    Division of Dermatology, Department of Medicine, University of Toronto, ON, Canada; Sunnybrook Health Sciences Centre, Toronto, ON, Canada; Women's College Hospital, Toronto, ON, Canada; Probity Medical Research Inc, Waterloo, ON, Canada. Electronic address:

    Efficacy and safety of ixekizumab in patients with plaque psoriasis across different degrees of disease severity: results from UNCOVER-2 and UNCOVER-3.
    J Dermatolog Treat 2018 Jun 12:1-8. Epub 2018 Jun 12.
    e Department of Dermatology , Paul Sabatier University and CHU Toulouse , Toulouse , France.
    Purpose: To evaluate short- and long-term efficacy and safety of ixekizumab in patients according to psoriasis severity.

    Materials And Methods: Data were integrated from clinical trials (UNCOVER-2, UNCOVER-3). Patients received placebo, 80-mg ixekizumab every 2 weeks (IXEQ2W), every 4 weeks (IXEQ4W), or 50 mg etanercept (ETN) biweekly for 12 weeks, then open-label IXEQ4W (UNCOVER-3). Read More

    1 OF 75